- Home
- RERE vs ACRS Comparison
RERE vs ACRS Comparison
Compare RERE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | ACRS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 868.5M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RERE | ACRS |
|---|---|---|
| Price | $4.11 | $6.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $22.93 | $4.24 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $1.74 |
| 52 Week High | $6.47 | $6.52 |
Technical Indicators
Market Signals| Indicator | RERE | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 63.19 |
| Support Level | $3.96 | $5.64 |
| Resistance Level | $4.29 | $6.52 |
| Average True Range (ATR) | 0.17 | 0.33 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 13.04 | 82.29 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.